title: Speech dysfunction in early Parkinson's disease.
abstract: The purpose of this study is to determine if subjects in the early stages of untreated Parkinson's disease (PD) or PD treated with deprenyl alone suffer from motor speech abnormalities. Speech defects are common in advanced PD, including disturbances of respiration, phonation, and articulation. We studied 12 subjects with early PD (Hoehn and Yahr stage < or = 2, mean duration disease 3.2 years) who were not taking symptomatic therapy and tested them under two conditions: on and off deprenyl. None of the subjects was depressed or demented (Mini Mental Status mean 29.9/30; Hamilton Depression Rating mean 2.7/52). All functioned independently (Schwab and England Activities of Daily Living mean 93.1/100). Acoustic and speech productions were assessed using the DSP Sona-Graph 5500 and an evaluation of dysarthria. All 12 had at least two characteristics of dysarthria on examination, although 8 were not aware of it. Vocal tremor was identified on narrow band spectrogram for four subjects. Deprenyl did not have a consistent effect on speech. Ten subjects had no detectable change in speech on deprenyl, one was worse, and one was improved.
authors.affiliation: Department of Speech-Language Pathology and Audiology, New York University 10003-6674, USA.
authors.forename: C
authors.initials: C
authors.lastname: Stewart
authors.forename: L
authors.initials: L
authors.lastname: Winfield
authors.forename: A
authors.initials: A
authors.lastname: Hunt
authors.forename: S B
authors.initials: SB
authors.lastname: Bressman
authors.forename: S
authors.initials: S
authors.lastname: Fahn
authors.forename: A
authors.initials: A
authors.lastname: Blitzer
authors.forename: M F
authors.initials: MF
authors.lastname: Brin
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001184:Articulation Disorders / Q000150:complications*; D004401:Dysarthria / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D012642:Selegiline / Q000008:administration & dosage / Q000627:therapeutic use; D012720:Severity of Illness Index; D014832:Voice Disorders / Q000150:complications*
chemical_list: D000978:Antiparkinson Agents; D012642:Selegiline